11. 重症筋無力症 Disease details / Clinical trials / Drug dev / DR info

250 MG CK-2017357
   Cytokinetics
      2010   Phase 2   NCT01268280   United States
500 MG CK-2017357
   Cytokinetics
      2010   Phase 2   NCT01268280   United States
Abatacept injection
   Johns Hopkins University
      2017   Early Phase 1   NCT03059888   United States
Acetaminophen
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States
Acetate
   Peking University People's Hospital
      2024   Phase 2   ChiCTR2400084781   China
Acotiamide
   Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine
      2024   -   JPRN-UMIN000053000   Japan
Addition OF rituximab IF recurrence
   Fondation Ophtalmologique Adolphe de Rothschild
      2024   Phase 3   NCT06342544   -
ALN-CC5
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003272-41-FR   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-ES   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Georgia;Germany;India;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-DE   Australia;Belgium;Brazil;Canada;Denmark;France;Georgia;Germany;India;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-BE   Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Georgia;Germany;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003272-41-PL   Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
ALXN1210
   ALEXION PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2018-003243-39-IT   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States
   Alexion Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2018-003243-39-PT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003243-39-GB   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003243-39-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-NL   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-ES   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-DK   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-DE   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-AT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States
   Terada Michinori
      2023   Phase 3   JPRN-jRCT2031230150   France;Germany;Italy;Japan;Netherlands;Serbia;Spain;Switzerland;United States of America
ALXN1720
   Alexion Pharmaceuticals, Inc
      2023   Phase 3   EUCTR2022-000460-21-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2023   Phase 3   EUCTR2022-000460-21-PL   Argentina;Austria;Brazil;Canada;China;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2023   Phase 3   EUCTR2022-000460-21-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2023   Phase 3   EUCTR2022-000460-21-AT   Argentina;Austria;Brazil;Canada;China;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000460-21-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000460-21-DK   Argentina;Austria;Brazil;Canada;China;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000460-21-DE   Argentina;Austria;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
ALXN1830
   Alexion Pharmaceuticals
      2022   Phase 2   NCT04982289   United States
ALXN2050
   Alexion Pharmaceuticals
      2022   Phase 2   EUCTR2021-001229-26-ES   Canada;Germany;Italy;Korea, Democratic People's Republic of;Spain;Taiwan;United States
      2022   Phase 2   EUCTR2021-001229-26-DE   Canada;Germany;Italy;Korea, Democratic People's Republic of;Serbia;Spain;Taiwan;United States
   Alexion Pharmaceuticals, Inc.
      2022   Phase 2   NCT05218096   Canada;Germany;Italy;Korea, Republic of;Serbia;Spain;Taiwan;United States
Amifampridina
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2015   Phase 2   EUCTR2015-003127-62-IT   Italy
Amifampridina fosfato
   CATALYST PHARMACEUTICALS INC.
      2018   Phase 3   EUCTR2017-004777-14-IT   Canada;Italy;United States
      2018   Phase 3   EUCTR2017-004018-25-IT   Canada;Italy;United States
Amifampridine
   Leiden University Medical Center
      2022   Phase 3;Phase 4   EUCTR2021-004110-20-NL   Netherlands
Amifampridine (base) with modified release
   Leiden University Medical Center
      2023   Phase 3   NCT05919407   Netherlands
Amifampridine phosphate
   Catalyst Pharmaceuticals, Inc.
      2018   Phase 3   NCT03579966   United States
      2018   Phase 3   NCT03304054   United States
Anito-CEL
   Arcellx, Inc.
      2025   Phase 1   NCT06626919   United States
ANTI-C5 antibody
   Alexion Pharmaceuticals Inc.
      2009   -   EUCTR2009-014669-13-GB   United Kingdom
ANTI-thymocyte globulin
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
Apraclonidine HCL 0.5% OPH soln
   American University of Beirut Medical Center
      2020   Phase 2   NCT05045248   Lebanon
ARGX-113
   ARGEN-X BVBA
      2018   Phase 3   EUCTR2018-002133-37-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2018-002132-25-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2016   Phase 2   EUCTR2016-002938-73-IT   Belgium;Canada;Italy;Netherlands;Poland;Spain;Sweden;United States
   ARGENX BV
      2022   Phase 3   EUCTR2021-002504-12-IT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-IT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2020-005841-18-IT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004086-38-IT   Belgium;Bosnia and Herzegovina;Canada;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-IT   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
   Argenx BVBA
      2018   Phase 3   EUCTR2018-002132-25-DK   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2016   Phase 2   EUCTR2016-002938-73-NL   Belgium;Canada;Italy;Netherlands;Poland;Spain;Sweden;United States
      2016   Phase 2   EUCTR2016-002938-73-ES   Belgium;Canada;Italy;Netherlands;Poland;Spain;Sweden;United States
      2016   Phase 2   EUCTR2016-002938-73-BE   Belgium;Canada;Italy;Netherlands;Poland;Spain;Sweden;United States
   argenx
      2018   Phase 3   NCT03669588   Belgium;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;United Kingdom;United States
      2016   Phase 2   NCT02965573   Belgium;Canada;Italy;Netherlands;Poland;Spain;Sweden;United States
   argenx BV
      2022   Phase 3   EUCTR2021-002504-12-NL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002504-12-FR   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002504-12-DE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002504-12-BE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-NL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-FR   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-ES   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-DE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-BE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-AT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2020-005841-18-NL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2020-005841-18-DE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2020-005841-18-AT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2021-002504-12-PL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2021-002504-12-ES   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2020-005841-18-FR   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2020-005841-18-ES   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2020-005841-18-BE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004086-38-NL   Belgium;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-004086-38-HU   Belgium;Bosnia and Herzegovina;Canada;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004086-38-ES   Belgium;Bosnia and Herzegovina;Canada;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004086-38-DE   Belgium;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-004086-38-CZ   Belgium;Bosnia and Herzegovina;Canada;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004086-38-BE   Belgium;Bosnia and Herzegovina;Canada;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-NL   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-HU   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-ES   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-DE   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-BE   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-002460-46-PL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2020-005841-18-PL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2020-005841-18-Outside-EU/EEA   Canada;Georgia;United Kingdom;United States
   argenx BVBA
      2019   Phase 3   EUCTR2018-002133-37-NL   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002133-37-HU   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002133-37-DK   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002133-37-DE   Belgium;Canada;Czech Republic;Czechia;Denmark;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;United States
      2019   Phase 3   EUCTR2018-002133-37-CZ   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002133-37-BE   Belgium;Canada;Czech Republic;Denmark;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;United States
      2019   Phase 3   EUCTR2018-002132-25-NL   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002132-25-HU   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002132-25-FR   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002132-25-DE   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002132-25-CZ   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002132-25-BE   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
Autologous hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
AZA
   Qualitix Clinical Research Co., Ltd.
      2009   -   NCT00997412   -
Azathioprine
   Duke University
      2018   -   NCT03490539   Canada;United States
   First Affiliated Hospital, Sun Yat-Sen University
      2012   Phase 3   NCT01727193   China
   Neurology Department of the 940th Hospital of Joint Logistics Support force of Chinese People's Liberation Army
      2018   -   ChiCTR1900024692   China
B-peptide-CRM197 conjugate
   CuraVac Europe SA
      2017   Phase 2;Phase 3   EUCTR2017-000323-27-NL   Belgium;Netherlands
      2017   Phase 2;Phase 3   EUCTR2017-000323-27-BE   Belgium;Netherlands
B007
   Shanghai Jiaolian Drug Research and Development Co., Ltd
      2024   Phase 2/Phase 3   NCT06447597   China
Batoclimab
   Immunovant Sciences GmbH
      2023   Phase 3   EUCTR2021-000249-42-RO   Argentina;Brazil;Canada;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-000249-42-HU   Argentina;Australia;Brazil;Canada;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000249-42-PL   Argentina;Brazil;Canada;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000249-42-IT   Argentina;Australia;Brazil;Canada;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Yamazaki Kenji
      2023   Phase 3   JPRN-jRCT2021230001   Argentina;Brazil;Canada;Georgia;Germany;Hungary;Italy;Japan;Mexico;Poland;Romania;Serbia;South Korea;Spain;UK;US
Batoclimab 340 MG SC BI-weekly
   Immunovant Sciences GmbH
      2022   Phase 3   NCT05403541   Argentina;Brazil;Canada;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
Batoclimab 340 MG SC weekly
   Immunovant Sciences GmbH
      2022   Phase 3   NCT05403541   Argentina;Brazil;Canada;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
Batoclimab 680 MG SC weekly
   Immunovant Sciences GmbH
      2022   Phase 3   NCT05403541   Argentina;Brazil;Canada;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
BBR 2778
   ISTITUTO NEUROLOGICO CARLO BESTA
      2008   -   EUCTR2007-002817-37-IT   Italy
Belimumab
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2011   -   EUCTR2011-002068-26-IT   Canada;Germany;Italy;United States
   GlaxoSmithKline
      2013   Phase 2   NCT01480596   Canada;Germany;Italy;United States
   GlaxoSmithKline Research & Development Limited
      2011   -   EUCTR2011-002068-26-DE   Canada;Germany;Italy;United States
Bexsero
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
Blinatumomab
   Da, Yuwei, M.D.
      2025   Phase 2/Phase 3   NCT06836973   -
   Second Affiliated Hospital of Army Medical University
      2024   Phase 2-3   ChiCTR2400093064   China
   Zhongming Qiu
      2024   Phase 2/Phase 3   NCT06684184   -
Bortezomib
   Charite University, Berlin, Germany
      2014   Phase 2   NCT02102594   Germany
   Charité - Universitätsmedizin Berlin
      2014   Phase 2   EUCTR2013-005362-19-DE   Germany
BU zhong YI QI tang
   Cheng, yu-ting
      2022   -   NCT06881173   Taiwan
CABA-201
   Cabaletta Bio
      2024   Phase 1/Phase 2   NCT06359041   United States
Carmustine
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
CC-97540
   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
      2024   Phase 1   NCT06220201   Belgium;France;Germany;Italy;Spain;United Kingdom;United States
CD19-bcma targeted CAR-T dose 1
   Ting Chang, MD
      2024   Phase 1   NCT06371040   China
CD19-bcma targeted CAR-T dose 2
   Ting Chang, MD
      2024   Phase 1   NCT06371040   China
CD19-directed humanised afucosylated monoclonal antibody
   Viela Bio, Inc.
      2020   Phase 3   EUCTR2020-000949-14-FR   Argentina;Australia;Belarus;Brazil;Canada;China;Denmark;Finland;France;Germany;Guatemala;India;Israel;Italy;Japan;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   Viela Bio, Inc. /Horizon Therapeutics Ireland DAC
      2021   Phase 3   EUCTR2020-000949-14-DE   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Türkiye;Ukraine;United Kingdom;United States
   Viela Bio, Inc./Horizon Therapeutics Ireland DAC
      2021   Phase 3   EUCTR2020-000949-14-DK   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
CD20/BCMA-directed CAR-T cells
   RenJi Hospital
      2024   Phase 1   NCT06249438   China
Cellcept
   ASPREVA PHARMACEUTICALS CORPORATION
      2006   -   EUCTR2005-000343-28-IT   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-000596-34-IT   Czech Republic;Hungary;Italy;Spain
   Hoffmann-La Roche
      2004   Phase 3   NCT00683969   Canada;Former Serbia and Montenegro;France;Germany;India;Israel;Italy;Mexico;Netherlands;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2004   Phase 3   NCT00408213   Canada;Czech Republic;Former Serbia and Montenegro;France;Germany;Israel;Italy;Mexico;Netherlands;Spain;Ukraine;United Kingdom;United States
Cellcept 500 MG
   F.Hoffmann-La Roche Ltd.
      2005   -   EUCTR2004-000596-34-CZ   Czech Republic;Hungary;Italy;Spain
Cellcept 500 MG FILM-coated tablets
   F. Hoffmann-La Roche Ltd
      2005   Phase 3   EUCTR2004-000596-34-ES   Czech Republic;Hungary;Italy;Spain
   F. Hoffmann-La Roche Ltd as part of the Aspreva Rare Disease Program
      2005   -   EUCTR2004-000596-34-HU   Czech Republic;Hungary;Italy;Spain
Cellcept 500 MG tablets
   Aspreva Pharmaceutical Corporation
      2005   -   EUCTR2005-000343-28-GB   Germany;Italy;Spain;United Kingdom
   Aspreva Pharmaceuticals Corporation
      2005   -   EUCTR2005-000343-28-DE   Germany;Italy;Spain;United Kingdom
Cellcept®500 MG tablets
   F. Hoffmann-La Roche Ltd
      2005   Phase 3   EUCTR2004-000596-34-ES   Czech Republic;Hungary;Italy;Spain
   F. Hoffmann-La Roche Ltd as part of the Aspreva Rare Disease Program
      2005   -   EUCTR2004-000596-34-HU   Czech Republic;Hungary;Italy;Spain
Cemdisiran
   Pavani Rodrigo
      2022   Phase 3   JPRN-jRCT2071220059   Australia;Belgium;Canada;China;Denmark;France;Georgia;Germany;India;Italy;Japan;Poland;Serbia;South Korea;Spain;Taiwan;Turkey;UK;United States
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003272-41-FR   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-ES   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Georgia;Germany;India;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-DE   Australia;Belgium;Brazil;Canada;Denmark;France;Georgia;Germany;India;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-BE   Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Georgia;Germany;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003272-41-PL   Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
CFZ533
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2015-000097-35-DK   Canada;Denmark;Germany;Russian Federation;Taiwan
      2015   Phase 2   EUCTR2015-000097-35-DE   Canada;Denmark;Germany;Russian Federation;Taiwan
   Novartis Pharmaceuticals
      2015   Phase 2   NCT02565576   Canada;Denmark;Germany;Russian Federation;Taiwan
Cladribine
   Medical University of Lublin
      2021   Phase 2   EUCTR2020-005762-34-PL   Poland
Cladribine high dose
   Ishii Kyoko
      2024   Phase 3   JPRN-jRCT2031240175   Argentina;Australia;Brazil;France;Georgia;Germany;Italy;Japan;Korea;Poland;Spain;Taiwan;United Kingdom;United States
   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
      2024   Phase 3   NCT06463587   Argentina;Australia;Georgia;Germany;Japan;Korea, Republic of;Poland;Taiwan;United Kingdom;United States
Cladribine LOW dose
   Ishii Kyoko
      2024   Phase 3   JPRN-jRCT2031240175   Argentina;Australia;Brazil;France;Georgia;Germany;Italy;Japan;Korea;Poland;Spain;Taiwan;United Kingdom;United States
   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
      2024   Phase 3   NCT06463587   Argentina;Australia;Georgia;Germany;Japan;Korea, Republic of;Poland;Taiwan;United Kingdom;United States
Cladrybine
   Medical University of Lublin
      2021   Phase 2   EUCTR2020-005762-34-PL   Poland
CNP-106
   COUR Pharmaceutical Development Company, Inc.
      2024   Phase 1/Phase 2   NCT06106672   United States
CT103A cells
   Tongji Hospital
      2020   Early Phase 1   NCT04561557   China
CV-MG01
   CuraVac
      2018   Phase 2/Phase 3   NCT03165435   Belgium;Netherlands
      2016   Phase 1/Phase 2   NCT02609022   Belgium
   CuraVac Europe SA
      2017   Phase 2;Phase 3   EUCTR2017-000323-27-NL   Belgium;Netherlands
      2017   Phase 2;Phase 3   EUCTR2017-000323-27-BE   Belgium;Netherlands
Cyclophosphamide
   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
      2024   Phase 1   NCT06220201   Belgium;France;Germany;Italy;Spain;United Kingdom;United States
   Northwestern University
      2002   Phase 1   NCT00424489   United States
Cyclophosphamide and fludarabine
   Tongji Hospital
      2020   Early Phase 1   NCT04561557   China
Cyclosporine
   Neurology Department of the 940th Hospital of Joint Logistics Support force of Chinese People's Liberation Army
      2018   -   ChiCTR1900024692   China
Cytarabine
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
DAS-001
   DAS-MG, Inc
      2023   Phase 2   NCT04226170   United States
Decartes-08
   Cartesian Therapeutics
      2025   Phase 3   NCT06799247   United States
Descartes-08
   Cartesian Therapeutics
      2019   Phase 2   NCT04146051   Canada;United States
Difenidramina cloridrato
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States
Diphenhydramine hydrochloride
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States
DNTH103
   Dianthus Therapeutics
      2024   Phase 2   NCT06282159   Argentina;Canada;Czech Republic;Czechia;Denmark;France;Israel;Italy;Macedonia, The Former Yugoslav Republic of;Netherlands;North Macedonia;Norway;Poland;Serbia;Sweden;United States
Eculizumab
   Alexion Pharmaceuticals
      2014   Phase 3   NCT02301624   Argentina;Belgium;Brazil;Canada;Czechia;Denmark;Finland;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Sweden;Turkey;United Kingdom;United States
      2013   Phase 3   NCT01997229   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Sweden;Turkey;United Kingdom;United States
      2008   Phase 2   NCT00727194   Canada;United Kingdom;United States
   Alexion Pharmaceuticals Inc.
      2009   -   EUCTR2009-014669-13-GB   United Kingdom
   Alexion Pharmaceuticals, Inc.
      2025   Phase 3   NCT06764160   China
      2021   Phase 3   EUCTR2016-001384-37-NL   Canada;Germany;Japan;Netherlands;United States
      2020   Phase 3   EUCTR2016-001384-37-DE   Canada;Germany;Japan;Netherlands;United States
      2018   Phase 3   NCT03759366   Japan;Netherlands;United States
      2015   Phase 3   EUCTR2013-003589-15-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-003589-15-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002191-41-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002191-41-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002191-41-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom
      2015   Phase 3   EUCTR2013-002191-41-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002191-41-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002191-41-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   -   EUCTR2013-003589-15-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002191-41-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002191-41-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002191-41-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   -   EUCTR2013-002191-41-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002191-41-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   Peking University People's Hospital
      2024   Phase 2   ChiCTR2400084781   China
Efalizumab
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal
      2008   Phase 4   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal
Efgartigimod
   ARGEN-X BVBA
      2018   Phase 3   EUCTR2018-002133-37-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2018-002132-25-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
   ARGENX BV
      2022   Phase 3   EUCTR2021-002504-12-IT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
   Argenx BVBA
      2018   Phase 3   EUCTR2018-002132-25-DK   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
   Peking University People's Hospital
      2024   Phase 2   ChiCTR2400084937   China
      2024   Phase 2   ChiCTR2400084781   China
   University Health Network, Toronto
      2023   Phase 3   NCT06587867   Canada
   University of Colorado, Denver
      2025   Phase 4   NCT06860633   United States
   argenx
      2024   -   NCT06298565   Belgium;United States
      2023   -   NCT06299748   United States
      2022   -   NCT04777734   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United States
   argenx BV
      2022   Phase 3   EUCTR2021-002504-12-AT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
   argenx BVBA
      2019   Phase 3   EUCTR2018-002133-37-NL   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002133-37-BE   Belgium;Canada;Czech Republic;Denmark;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;United States
      2019   Phase 3   EUCTR2018-002132-25-NL   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002132-25-HU   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002132-25-FR   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002132-25-DE   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002132-25-CZ   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002132-25-BE   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
Efgartigimod + telitacicept (1-week interval) group
   First Affiliated Hospital of Wenzhou Medical University
      2025   -   NCT06827587   -
Efgartigimod + telitacicept (2-week interval) group
   First Affiliated Hospital of Wenzhou Medical University
      2025   -   NCT06827587   -
Efgartigimod administration
   Clinique Neuro-Outaouais
      2025   Phase 3   NCT06765161   Canada
Efgartigimod alfa
   ARGENX BV
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-IT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2020-005841-18-IT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004086-38-IT   Belgium;Bosnia and Herzegovina;Canada;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-IT   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
   argenx BV
      2022   Phase 3   EUCTR2021-002504-12-NL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002504-12-FR   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002504-12-DE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002504-12-BE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-NL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-FR   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-ES   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-DE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-BE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002460-46-AT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2020-005841-18-NL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2020-005841-18-DE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2020-005841-18-AT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2021-002504-12-PL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2021-002504-12-ES   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2020-005841-18-FR   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2020-005841-18-ES   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2020-005841-18-BE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004086-38-NL   Belgium;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-004086-38-HU   Belgium;Bosnia and Herzegovina;Canada;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004086-38-ES   Belgium;Bosnia and Herzegovina;Canada;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004086-38-DE   Belgium;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-004086-38-CZ   Belgium;Bosnia and Herzegovina;Canada;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004086-38-BE   Belgium;Bosnia and Herzegovina;Canada;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-NL   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-HU   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-ES   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-DE   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-BE   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-002460-46-PL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2020-005841-18-PL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2020-005841-18-Outside-EU/EEA   Canada;Georgia;United Kingdom;United States
   argenx BVBA
      2019   Phase 3   EUCTR2018-002133-37-HU   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002133-37-DK   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002133-37-DE   Belgium;Canada;Czech Republic;Czechia;Denmark;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;United States
      2019   Phase 3   EUCTR2018-002133-37-CZ   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;United Kingdom;United States
Efgartigimod concentrate FOR solution FOR infusion 20 MG/ML
   argenx
      2021   Phase 3   NCT04980495   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United States
Efgartigimod IV
   ARGENX BV
      2021   Phase 3   EUCTR2020-004085-19-IT   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
   argenx
      2024   Phase 3   NCT06298552   Belgium;Canada;China;Cyprus;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Netherlands;Norway;Poland;Portugal;Romania;Saudi Arabia;Serbia;Spain;United Kingdom;United States
      2021   Phase 2/Phase 3   NCT04833894   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 3   NCT04735432   Belgium;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
   argenx BV
      2021   Phase 3   EUCTR2020-004085-19-NL   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-HU   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-ES   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-DE   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-BE   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
Efgartigimod IV or efgartigimod PH20 SC
   argenx
      2022   Phase 2/Phase 3   NCT05374590   Austria;Belgium;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Efgartigimod PH20 SC
   ARGENX BV
      2021   Phase 3   EUCTR2020-004086-38-IT   Belgium;Bosnia and Herzegovina;Canada;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-IT   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
   argenx
      2025   Phase 4   NCT06909214   -
      2024   Phase 2/Phase 3   NCT06392386   Belgium;France;Israel;Italy;Netherlands;Poland;Spain;United States
      2021   Phase 3   NCT04818671   Belgium;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
      2021   Phase 3   NCT04735432   Belgium;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
   argenx BV
      2021   Phase 3   EUCTR2020-004086-38-NL   Belgium;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-004086-38-HU   Belgium;Bosnia and Herzegovina;Canada;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004086-38-ES   Belgium;Bosnia and Herzegovina;Canada;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004086-38-DE   Belgium;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-004086-38-CZ   Belgium;Bosnia and Herzegovina;Canada;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004086-38-BE   Belgium;Bosnia and Herzegovina;Canada;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-NL   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-HU   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-ES   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-DE   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004085-19-BE   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
EN101
   Ester Neuroscience Ltd
      2006   Phase 2   EUCTR2005-002740-26-GB   United Kingdom
Ephedrine hydrochloride
   Leiden University Medical Center
      2014   -   EUCTR2014-001355-23-NL   Netherlands
Etomidate
   Shenzhen Guangming District People's Hospital
      2024   Phase 4   ChiCTR2400084414   China
Etoposide
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
Famciclovir
   Tianjin Medical University affiliated General Hospital
      2021   -   ChiCTR2100049088   China
      2021   -   ChiCTR2100048785   China
FC- and CDR-modified humanised monoclonal antibody against C5
   Alexion Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2018-003243-39-PT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003243-39-GB   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003243-39-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-NL   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-ES   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-DK   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-DE   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-AT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States
Firdapse - 10 MG - compresse - USO orale - blister(ALU/PVC/pvdc) 100 X 1 compresse
   CATALYST PHARMACEUTICALS INC.
      2018   Phase 3   EUCTR2017-004777-14-IT   Canada;Italy;United States
      2018   Phase 3   EUCTR2017-004018-25-IT   Canada;Italy;United States
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2015   Phase 2   EUCTR2015-003127-62-IT   Italy
Fludarabine
   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
      2024   Phase 1   NCT06220201   Belgium;France;Germany;Italy;Spain;United Kingdom;United States
G-CSF
   Northwestern University
      2002   Phase 1   NCT00424489   United States
Galantamine
   wenzhou peoples hospital
      2024   -   ChiCTR2400082365   China
GC012F injection
   Zhejiang University
      2024   Early Phase 1   NCT06419166   China
Gefurulimab
   Alexion Pharmaceuticals, Inc
      2023   Phase 3   EUCTR2022-000460-21-PL   Argentina;Austria;Brazil;Canada;China;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2023   Phase 3   EUCTR2022-000460-21-AT   Argentina;Austria;Brazil;Canada;China;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000460-21-DK   Argentina;Austria;Brazil;Canada;China;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2024   Phase 3   NCT06607627   Brazil;Poland;Taiwan;United States
Genotype analysis FOR VDR RS1544410, RS2228570, RS731236, and RS7975232 polymorphisms
   Beijing Tongren Hospital
      2017   -   NCT05380128   China
GSK1550188
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2011   -   EUCTR2011-002068-26-IT   Canada;Germany;Italy;United States
   GlaxoSmithKline Research & Development Limited
      2011   -   EUCTR2011-002068-26-DE   Canada;Germany;Italy;United States
Hematopoietic stem cell transplantation
   Northwestern University
      2002   Phase 1   NCT00424489   United States
Hidrocloruro DE efedrina
   Leiden University Medical Center
      2014   -   EUCTR2014-001355-23-NL   Netherlands
HN2301 injection
   Shenzhen MagicRNA Biotechnology Co., Ltd
      2025   -   NCT06965309   China
Human normal immunoglobulin
   Grifols Therapeutics Inc.
      2016   Phase 2   EUCTR2014-003997-18-DE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-LT   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-HU   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-EE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-CZ   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-BE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-LT   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-HU   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-DE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-CZ   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-BE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 3   EUCTR2013-005098-28-RO   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Latvia;Poland;Romania;Russian Federation
      2015   Phase 3   EUCTR2013-005098-28-PL   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa
      2015   Phase 3   EUCTR2013-005098-28-BE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Israel;Korea, Republic of;Latvia;Netherlands;Poland;Romania;Russian Federation;South Africa
      2014   Phase 3   EUCTR2013-005098-28-HU   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Netherlands;Poland;Romania;Russian Federation;South Africa
   Grifols Therapeutics LLC
      2015   Phase 2   EUCTR2013-005099-17-EE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 3   EUCTR2013-005098-28-LV   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa
      2015   Phase 3   EUCTR2013-005098-28-EE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa
   Grifols Therapeutics LLC.
      2015   Phase 3   EUCTR2013-005098-28-CZ   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa
   University of Alberta
      2014   Phase 3   NCT02774239   Canada
Humanised VHH-type bispecific antibody against complement component 5 and serum albumin
   Alexion Pharmaceuticals, Inc
      2023   Phase 3   EUCTR2022-000460-21-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2023   Phase 3   EUCTR2022-000460-21-PL   Argentina;Austria;Brazil;Canada;China;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2023   Phase 3   EUCTR2022-000460-21-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2023   Phase 3   EUCTR2022-000460-21-AT   Argentina;Austria;Brazil;Canada;China;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000460-21-DK   Argentina;Austria;Brazil;Canada;China;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000460-21-DE   Argentina;Austria;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
IGIV-C
   Grifols Therapeutics Inc.
      2016   Phase 2   EUCTR2014-003997-18-DE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-LT   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-HU   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-EE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-CZ   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-BE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-LT   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-HU   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-DE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-CZ   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-BE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
   Grifols Therapeutics LLC
      2015   Phase 2   NCT02473965   Belgium;Canada;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   NCT02473952   Belgium;Canada;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 3   NCT02413580   Argentina;Belgium;Canada;Czech Republic;Czechia;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa
      2015   Phase 2   EUCTR2013-005099-17-EE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
Immediate treatment with corticosteroids
   Fondation Ophtalmologique Adolphe de Rothschild
      2024   Phase 3   NCT06342544   -
Immune globulin
   University of Texas
      1995   -   NCT00004682   -
Immune globulin (human), 10% caprylate/chromatography purified
   Grifols Therapeutics Inc.
      2016   Phase 2   EUCTR2014-003997-18-DE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-LT   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-HU   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-EE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-CZ   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2014-003997-18-BE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-LT   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-HU   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-DE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-CZ   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 2   EUCTR2013-005099-17-BE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 3   EUCTR2013-005098-28-RO   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Latvia;Poland;Romania;Russian Federation
      2015   Phase 3   EUCTR2013-005098-28-PL   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa
      2015   Phase 3   EUCTR2013-005098-28-BE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Israel;Korea, Republic of;Latvia;Netherlands;Poland;Romania;Russian Federation;South Africa
      2014   Phase 3   EUCTR2013-005098-28-HU   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Netherlands;Poland;Romania;Russian Federation;South Africa
   Grifols Therapeutics LLC
      2015   Phase 2   EUCTR2013-005099-17-EE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States
      2015   Phase 3   EUCTR2013-005098-28-LV   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa
      2015   Phase 3   EUCTR2013-005098-28-EE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa
   Grifols Therapeutics LLC.
      2015   Phase 3   EUCTR2013-005098-28-CZ   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa
Immunoglobulin G
   University of Alberta
      2014   Phase 3   NCT02774239   Canada
   Vall d'Hebron Institut de Recerca (VHIR)
      2012   -   EUCTR2012-001544-21-ES   Spain
IMVT-1401
   Immunovant Sciences GmbH
      2023   Phase 3   EUCTR2021-000249-42-RO   Argentina;Brazil;Canada;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-000249-42-HU   Argentina;Australia;Brazil;Canada;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000249-42-PL   Argentina;Brazil;Canada;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000249-42-IT   Argentina;Australia;Brazil;Canada;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
Inebilizumab
   Amgen
      2025   Phase 2   NCT06987539   -
      2020   Phase 3   NCT04524273   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United States
   Cardona Ritsuko
      2021   Phase 3   JPRN-jRCT2021210003   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Poland;Russia;South Korea;Spain;Taiwan;Turkey;USA;Ukraine
   Viela Bio, Inc.
      2020   Phase 3   EUCTR2020-000949-14-FR   Argentina;Australia;Belarus;Brazil;Canada;China;Denmark;Finland;France;Germany;Guatemala;India;Israel;Italy;Japan;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   Viela Bio, Inc. /Horizon Therapeutics Ireland DAC
      2021   Phase 3   EUCTR2020-000949-14-DE   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Türkiye;Ukraine;United Kingdom;United States
   Viela Bio, Inc./Horizon Therapeutics Ireland DAC
      2021   Phase 3   EUCTR2020-000949-14-DK   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Influenza vaccine
   LUMC
      2016   Phase 4   EUCTR2016-003138-26-NL   Netherlands
Intravenous immuneglobulin
   University Health Network, Toronto
      2004   Phase 3   NCT00306033   Canada
Iptacopan
   Novartis Pharmaceuticals
      2024   Phase 3   NCT06517758   China;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;United Kingdom;United States
IV efgartigimod
   Rambam Health Care Campus
      2024   Phase 4   NCT06688253   Israel
Ivig
   Da, Yuwei, M.D.
      2017   -   NCT04101578   China
   Kansai medical university
      2014   -   JPRN-UMIN000015019   Japan
   Shijiazhuang People’s Hospita
      2023   Phase 4   ChiCTR2400080921   China
   University Health Network, Toronto
      2007   Phase 4   NCT01179893   Canada
JNJ-80202135
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 3   EUCTR2020-005732-29-IT   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Janssen-Cilag International N.V.
      2022   Phase 3   EUCTR2020-005732-29-DK   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2022   Phase 3   EUCTR2020-005732-29-BE   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005732-29-SE   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005732-29-PL   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005732-29-ES   Australia;Belgium;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005732-29-DE   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005732-29-CZ   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Janssen-Cilag Invernational N.V.
      2023   Phase 2;Phase 3   EUCTR2021-002479-20-PL   Belgium;France;Germany;Italy;Japan;Netherlands;Poland;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002479-20-NL   Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Poland;United Kingdom;United States
   Nakano Masayoshi
      2021   Phase 3   JPRN-jRCT2021210027   Australia;Belgium;Canada;China;Colombia;Czechia;Denmark;France;Germany;Italy;Japan;Kingdom Of Great Britain And Northern Ireland;Korea Republic Of;Mexico;Poland;Spain;Sweden;Taiwan;United States Of America
KYV-101
   Kyverna Therapeutics
      2024   Phase 2   NCT06193889   Germany;United States
Laboratory biomarker analysis
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
LCAR-AIO T cells
   Wuhan Union Hospital, China
      2025   Phase 1   NCT06869278   China
Leflunomide
   First Affiliated Hospital, Sun Yat-Sen University
      2012   Phase 3   NCT01727193   China
M281
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 3   EUCTR2020-005732-29-IT   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Janssen-Cilag International N.V.
      2022   Phase 3   EUCTR2020-005732-29-DK   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2022   Phase 3   EUCTR2020-005732-29-BE   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005732-29-SE   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005732-29-PL   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005732-29-ES   Australia;Belgium;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005732-29-DE   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005732-29-CZ   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Janssen-Cilag Invernational N.V.
      2023   Phase 2;Phase 3   EUCTR2021-002479-20-PL   Belgium;France;Germany;Italy;Japan;Netherlands;Poland;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002479-20-NL   Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Poland;United Kingdom;United States
   MOMENTA PHARMACEUTICALS, Inc
      2019   Phase 2   EUCTR2018-003618-41-IT   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
   Momenta Pharmaceuticals, Inc.
      2019   Phase 2   NCT03896295   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   NCT03772587   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003618-41-PL   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003618-41-GB   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003618-41-DE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003618-41-BE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002247-28-GB   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
   Nakano Masayoshi
      2021   Phase 3   JPRN-jRCT2021210027   Australia;Belgium;Canada;China;Colombia;Czechia;Denmark;France;Germany;Italy;Japan;Kingdom Of Great Britain And Northern Ireland;Korea Republic Of;Mexico;Poland;Spain;Sweden;Taiwan;United States Of America
M281 injection
   MOMENTA PHARMACEUTICALS, Inc
      2019   Phase 2   EUCTR2018-002247-28-IT   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
   Momenta Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2018-003618-41-ES   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002247-28-PL   Belgium;Canada;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002247-28-BE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2018-002247-28-ES   Belgium;Canada;France;Germany;Italy;Poland;Spain;United Kingdom;United States
Mabthera
   Karolinska Institutet
      2016   Phase 3   EUCTR2015-005749-30-SE   Sweden
Magnesium sulfate
   The University of Hong Kong-Shenzhen Hospital
      2016   -   ChiCTR1800017696   China
Melphalan
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
Meningococcal group A oligosaccharides conjugated TO corynebacterium diphtheriae C7 (ß197) M8 (CRM197) protein
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States
Meningococcal group W oligosaccharides conjugated TO corynebacterium diphtheriae C7 (ß197) M8 (CRM197) protein
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States
Meningococcal group Y oligosaccharides conjugated TO corynebacterium diphtheriae C7 (Â197) M8 (CRM197) protein
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States
Menveo
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States
Mesna
   Northwestern University
      2002   Phase 1   NCT00424489   United States
Mestinon
   Aarhus University
      2017   Phase 4   EUCTR2017-002599-15-DK   Denmark
   Leiden University Medical Center
      2022   Phase 3;Phase 4   EUCTR2021-004110-20-NL   Netherlands
Methotrexate
   University of Kansas Medical Center
      2009   Phase 2   NCT00814138   Canada;United States
   Xuan Wu Hospital, Capital Medical University
      2014   Phase 4   ChiCTR-IPR-15006081   -
Methylprednisolone
   Huashan Hospital Fudan University
      2023   Phase 0   ChiCTR2300073035   CHINA
   Koh Jinsoo
      2021   -   JPRN-jRCTs051200137   -
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States
   Northwestern University
      2002   Phase 1   NCT00424489   United States
   Shijiazhuang People’s Hospita
      2023   Phase 4   ChiCTR2400080921   China
   Sugimoto Takamichi
      2024   -   JPRN-jRCTs061240006   -
Metilprdnisolone
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States
Metilprednisolone
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States
Monarsen
   Ester Neuroscience Ltd
      2006   Phase 2   EUCTR2005-002740-26-GB   United Kingdom
Monitor
   Yijishan Hospital, Wannan Medical College, Wuhu 241001, China
      2014   -   ChiCTR-OCC-14004533   China
MUSK-caart
   Cabaletta Bio
      2022   Phase 1   NCT05451212   United States
Mutagrip
   Philipps-University
      2006   -   EUCTR2006-004374-27-DE   Germany
Mycophenolate mofetil
   Aspreva Pharmaceutical Corporation
      2005   -   EUCTR2005-000343-28-GB   Germany;Italy;Spain;United Kingdom
   Aspreva Pharmaceuticals Corporation
      2005   -   EUCTR2005-000343-28-DE   Germany;Italy;Spain;United Kingdom
   Duke University
      2018   -   NCT03490539   Canada;United States
   F. Hoffmann-La Roche Ltd
      2005   Phase 3   EUCTR2004-000596-34-ES   Czech Republic;Hungary;Italy;Spain
   F. Hoffmann-La Roche Ltd as part of the Aspreva Rare Disease Program
      2005   -   EUCTR2004-000596-34-HU   Czech Republic;Hungary;Italy;Spain
   FDA Office of Orphan Products Development
      2002   Phase 3   NCT00285350   -
   Hoffmann-La Roche
      2004   Phase 3   NCT00683969   Canada;Former Serbia and Montenegro;France;Germany;India;Israel;Italy;Mexico;Netherlands;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2004   Phase 3   NCT00408213   Canada;Czech Republic;Former Serbia and Montenegro;France;Germany;Israel;Italy;Mexico;Netherlands;Spain;Ukraine;United Kingdom;United States
Mycophenolic acid
   ASPREVA PHARMACEUTICALS CORPORATION
      2006   -   EUCTR2005-000343-28-IT   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-000596-34-IT   Czech Republic;Hungary;Italy;Spain
   Qualitix Clinical Research Co., Ltd.
      2009   -   NCT00997412   -
N. meningitidis group C (strain C11) oligosaccharide conjugated TO corynebacterium diphtheriae CRM197 adsorbed ON aluminum hydroxide
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States
Neostigmine
   Beijing Tongren Hospital
      2024   -   NCT06436768   China
   Beijing Tongren Hospital, Capital Medical University
      2022   -   ChiCTR2300073727   China
Nipocalimab
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 3   EUCTR2020-005732-29-IT   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Janssen Research & Development, LLC
      2022   Phase 2/Phase 3   NCT05265273   Canada;Japan;Netherlands;Poland;United States
      2021   Phase 3   NCT04951622   Australia;Belgium;Canada;China;Colombia;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Janssen-Cilag International N.V.
      2022   Phase 3   EUCTR2020-005732-29-DK   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2022   Phase 3   EUCTR2020-005732-29-BE   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005732-29-SE   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005732-29-PL   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005732-29-ES   Australia;Belgium;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005732-29-DE   Australia;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005732-29-CZ   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Janssen-Cilag Invernational N.V.
      2023   Phase 2;Phase 3   EUCTR2021-002479-20-PL   Belgium;France;Germany;Italy;Japan;Netherlands;Poland;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-002479-20-NL   Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Poland;United Kingdom;United States
Nipocalimab
   Janssen-Cilag International N.V.
      2022   Phase 3   EUCTR2020-005732-29-FR   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Nakano Masayoshi
      2022   Phase 2   JPRN-jRCT2031220102   Canada;Japan;Netherlands;nitedStates of America
      2021   Phase 3   JPRN-jRCT2021210027   Australia;Belgium;Canada;China;Colombia;Czechia;Denmark;France;Germany;Italy;Japan;Kingdom Of Great Britain And Northern Ireland;Korea Republic Of;Mexico;Poland;Spain;Sweden;Taiwan;United States Of America
NMD670
   NMD Pharma A/S
      2024   Phase 2   NCT06414954   Belgium;Denmark;France;Georgia;Italy;Netherlands;Poland;Serbia;Spain;United States
Ocrelizumab
   Peking University People's Hospital
      2024   Phase 2   ChiCTR2400084422   China
      2024   Phase 2   ChiCTR2400083807   China
      2024   Phase 2   ChiCTR2400083801   China
Ofatumumab
   Peking University People's Hospital
      2024   Phase 2   ChiCTR2400084937   China
Outer membrane vesicles (OMV) from neisseria meningitidis group B strain NZ98/254measured AS amount OF total protein containing THE pora P1.4
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
Oxaloacetate
   University of Kansas Medical Center
      2025   Phase 1   NCT04965987   United States
Paracetamolo
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States
Peripheral blood stem cell transplantation
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
Phosphate
   CATALYST PHARMACEUTICALS INC.
      2018   Phase 3   EUCTR2017-004777-14-IT   Canada;Italy;United States
      2018   Phase 3   EUCTR2017-004018-25-IT   Canada;Italy;United States
Pixantrone
   ISTITUTO NEUROLOGICO CARLO BESTA
      2008   -   EUCTR2007-002817-37-IT   Italy
Plasmapheresis
   Benesis Corporation
      2007   Phase 3   NCT00515450   Japan
Plex
   University Health Network, Toronto
      2007   Phase 4   NCT01179893   Canada
Pozelimab
   Pavani Rodrigo
      2022   Phase 3   JPRN-jRCT2071220059   Australia;Belgium;Canada;China;Denmark;France;Georgia;Germany;India;Italy;Japan;Poland;Serbia;South Korea;Spain;Taiwan;Turkey;UK;United States
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003272-41-FR   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-ES   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Georgia;Germany;India;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-DE   Australia;Belgium;Brazil;Canada;Denmark;France;Georgia;Germany;India;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-BE   Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Georgia;Germany;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003272-41-PL   Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
Pozelimab + cemdisiran
   Regeneron Pharmaceuticals
      2021   Phase 3   NCT05070858   Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Georgia;Germany;India;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Turkey;United Kingdom;United States
Prednisolone
   Department of Neurology, Chiba University Graduate School of Medicine
      2012   -   JPRN-UMIN000007679   Japan
      2012   -   JPRN-UMIN000007671   Japan
   Koh Jinsoo
      2021   -   JPRN-jRCTs051200137   -
Prednisone
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
   Michael Benatar
      2011   Phase 3   NCT00995722   Canada;United States
   The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
      2018   -   ChiCTR1800017564   China
   Xuan Wu Hospital, Capital Medical University
      2014   Phase 4   ChiCTR-IPR-15006081   -
Prednisone - azathioprine
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 4   NCT00987116   France
Prednisone alone
   University of Alabama at Birmingham
      2006   Phase 3   NCT00294658   Argentina;Australia;Brazil;Canada;Chile;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States
Privigen
   Vall d'Hebron Institut de Recerca (VHIR)
      2012   -   EUCTR2012-001544-21-ES   Spain
PRN2246
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 3   EUCTR2021-003898-59-IT   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
   Sanofi-Aventis Recherche & Développement
      2022   Phase 3   EUCTR2021-003898-59-PL   Argentina;Brazil;Canada;China;Czechia;Germany;Hungary;Italy;Japan;Mexico;Poland;Russian Federation;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003898-59-ES   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2021-003898-59-HU   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
Pyridostigmine
   Aarhus University
      2017   Phase 4   EUCTR2017-002599-15-DK   Denmark
   Leiden University Medical Center
      2023   Phase 3   NCT05919407   Netherlands
   Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine
      2010   Phase 1+Phase 2   ChiCTR-TRC-13004125   China
   University of Aarhus
      2018   Phase 4   NCT03510546   Denmark
Pyridostigmine bromide
   Affiliated Jiangmen Traditional Chinese Medicine Hospital of Ji’nan University
      2022   Phase 0   ChiCTR2100047506   China
   Leiden University Medical Center
      2022   Phase 3;Phase 4   EUCTR2021-004110-20-NL   Netherlands
   The first affiliated hospital of Guangzhou university of Traditional Chinese medicine
      2012   -   ChiCTR-OCC-13003090   China
Pyridostigmine, prednisone, tacrolimus
   Da, Yuwei, M.D.
      2021   -   NCT04768465   China
Pyridostigmine, tacrolimus
   Da, Yuwei, M.D.
      2021   -   NCT04768465   China
Rabbit
   Northwestern University
      2002   Phase 1   NCT00424489   United States
Raptiva 100 MG/ML powder and solvent FOR solution FOR injection
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal
      2008   Phase 4   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal
Ravulizumab
   ALEXION PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2018-003243-39-IT   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States
   Alexion Pharmaceuticals
      2019   Phase 3   NCT03920293   Austria;Canada;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United States
   Alexion Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2018-003243-39-PT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003243-39-GB   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003243-39-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-NL   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-ES   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-DK   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-DE   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-AT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2025   -   NCT06967480   Italy
      2023   Phase 3   NCT05644561   France;Italy;Japan;Netherlands;Serbia;Spain;Switzerland;United States
   AstraZeneca
      2025   -   NCT06909253   Poland
   Terada Michinori
      2023   Phase 3   JPRN-jRCT2031230150   France;Germany;Italy;Japan;Netherlands;Serbia;Spain;Switzerland;United States of America
RC18 160MG
   RemeGen Co., Ltd.
      2020   Phase 2   NCT04302103   China
RC18 240 MG
   RemeGen Co., Ltd.
      2020   Phase 2   NCT04302103   China
Recombinant neisseria meningitidis group B fhbp fusion protein produced IN E.coli cells BY recombinant DNA technology adsorbed ON aluminium hydroxide
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
Recombinant neisseria meningitidis group B nada protein
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
Recombinant neisseria meningitidis group B nhba fusion protein
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
REGN3918
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003272-41-FR   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-ES   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Georgia;Germany;India;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-DE   Australia;Belgium;Brazil;Canada;Denmark;France;Georgia;Germany;India;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003272-41-BE   Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Georgia;Germany;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003272-41-PL   Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
Remibrutinib
   Novartis Pharmaceuticals
      2025   Phase 3   NCT06744920   United States
Rituximab
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 2   NCT00774462   France
   Beijing Hospital
      2022   -   ChiCTR2200058984   China
   Department of Neurology University of Tokyo, Graduate School of Medicine
      2013   -   JPRN-UMIN000012089   Japan
   FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
      2021   Phase 3   EUCTR2020-005619-35-IT   Italy
   First Affiliated Hospital, Sun Yat-Sen University
      2020   Phase 3   NCT05332587   China
   Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      2022   Phase 3   NCT05868837   Italy
   Fredrik Piehl
      2016   Phase 3   NCT02950155   Sweden
   Karolinska Institutet
      2016   Phase 3   EUCTR2015-005749-30-SE   Sweden
   Peking University People's Hospital
      2024   Phase 2   ChiCTR2400084422   China
   Tokushima University Hospital
      2015   -   JPRN-UMIN000016564   Japan
   University of Vermont
      2004   Phase 1/Phase 2   NCT00619671   United States
   Yale University
      2014   Phase 2   NCT02110706   United States
RO 533-3787/F01-06
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-004436-21-PL   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   EUCTR2020-004436-21-NL   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   EUCTR2020-004436-21-DK   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   EUCTR2020-004436-21-DE   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
RO5333787
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-004436-21-IT   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-004436-21-PL   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   EUCTR2020-004436-21-NL   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   EUCTR2020-004436-21-FR   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   EUCTR2020-004436-21-DK   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   EUCTR2020-004436-21-DE   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-004436-21-ES   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
Rozanolixizumab
   Kaori Ikeda
      2023   Phase 3   JPRN-jRCT2021230009   Canada;Georgia;Germany;Italy;Japan;Poland;Serbia;Spain;United Kingdom;United States
   SUGIHARA Kazuhiro
      2021   Phase 3   JPRN-jRCT2021200038   Belgium;Canada;Czech Republic,;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;Taiwan;UK;US
   UCB Biopharma SPRL
      2020   Phase 3   EUCTR2019-000969-21-ES   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000969-21-HU   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-HU   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-GB   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-ES   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002698-36-DK   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States
      2017   Phase 2   EUCTR2016-002698-36-DE   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States
      2017   Phase 2   EUCTR2016-002698-36-CZ   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States
      2017   Phase 2   EUCTR2016-002698-36-BE   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States
   UCB Biopharma SRL
      2024   Phase 3   NCT06540144   Italy;Poland;Taiwan
      2024   Phase 2/Phase 3   NCT06149559   Italy;Poland;Taiwan;United States
      2023   Phase 3   NCT05681715   Canada;Georgia;Germany;Italy;Japan;Poland;Serbia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2022-003870-21-IT   Canada;Georgia;Germany;Italy;Japan;Poland;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   NCT04650854   Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;Taiwan;United States
      2021   Phase 3   EUCTR2020-003230-20-FR   Belgium;Canada;China;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003230-20-BE   Belgium;Canada;China;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-PL   Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-IT   Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-HU   Belgium;Canada;China;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-GB   Belgium;Canada;China;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-DK   Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-DE   Belgium;Canada;China;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-CZ   Belgium;Canada;China;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-000969-21-PL   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-000969-21-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-000969-21-GB   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-000969-21-DE   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-000969-21-CZ   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   NCT04124965   Canada;Czechia;Denmark;France;Germany;Italy;Japan;Poland;Russian Federation;Spain;Taiwan;United States
      2019   Phase 3   NCT03971422   Belgium;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000969-21-DK   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-PL   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-DK   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-DE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-CZ   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-BE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
   UCB Japan Co., Ltd.
      2020   Phase 3   JPRN-jRCT2080225254   Asia except Japan;Europe;Japan;North America
      2020   Phase 3   JPRN-jRCT2080225112   Asia except Japan;Europe;Japan;North America
RVT-1401
   Immunovant Sciences GmbH
      2019   Phase 2   NCT03863080   Canada;United States
RVT-1401, HL161BKN, HBM9161
   Immunovant Sciences GmbH
      2023   Phase 3   EUCTR2021-000249-42-RO   Argentina;Brazil;Canada;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-000249-42-HU   Argentina;Australia;Brazil;Canada;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000249-42-PL   Argentina;Brazil;Canada;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000249-42-IT   Argentina;Australia;Brazil;Canada;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Romania;Serbia;Spain;United Kingdom;United States
Salbutamol 4MG tablet
   University of Aarhus
      2019   Phase 2/Phase 3   NCT03914638   Denmark
Salbutamol WZF 4 MG
   Aarhus University Hospital
      2019   Phase 3   EUCTR2019-000895-40-DK   Denmark
SAR442168
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 3   EUCTR2021-003898-59-IT   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
   Sanofi-Aventis Recherche & Développement
      2022   Phase 3   EUCTR2021-003898-59-PL   Argentina;Brazil;Canada;China;Czechia;Germany;Hungary;Italy;Japan;Mexico;Poland;Russian Federation;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003898-59-ES   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2021-003898-59-HU   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
   Tanaka Tomoyuki
      2022   Phase 3   JPRN-jRCT2031220158   Canada;China;Hungary;Italy;Japan;Poland;Spainm;United Kingdo;United States
Satralizumab
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-004436-21-IT   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-004436-21-PL   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   EUCTR2020-004436-21-NL   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   EUCTR2020-004436-21-FR   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   EUCTR2020-004436-21-DK   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   EUCTR2020-004436-21-DE   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
   Hoffmann-La Roche
      2021   Phase 3   NCT04963270   Argentina;Australia;Brazil;Canada;China;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Turkey;United States
   Ivana Vodopivec
      2022   Phase 3   JPRN-jRCT2021210024   Argentina;Australia;Brazil;Canada;China;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Republic of Korea;Russian Federation;Spain;Taiwan;Turkey;United States
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-004436-21-ES   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States
Serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test,thymus CT, LOW frequency repeated nerve stimulation
   XiaoYong Liu
      2021   -   NCT05091177   China
Serum albumin
   Alexion Pharmaceuticals, Inc
      2022   Phase 3   EUCTR2022-000460-21-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Serbia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
Sodium chloride
   Huashan Hospital Fudan University
      2023   Phase 0   ChiCTR2300073035   CHINA
Sodium chloride solution
   Fredrik Piehl
      2016   Phase 3   NCT02950155   Sweden
Soliris
   Alexion Pharmaceuticals Inc.
      2009   -   EUCTR2009-014669-13-GB   United Kingdom
   Alexion Pharmaceuticals, Inc.
      2021   Phase 3   EUCTR2016-001384-37-NL   Canada;Germany;Japan;Netherlands;United States
      2020   Phase 3   EUCTR2016-001384-37-DE   Canada;Germany;Japan;Netherlands;United States
      2015   Phase 3   EUCTR2013-003589-15-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-003589-15-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002191-41-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002191-41-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002191-41-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom
      2015   Phase 3   EUCTR2013-002191-41-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002191-41-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-002191-41-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   -   EUCTR2013-003589-15-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-003589-15-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002191-41-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002191-41-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002191-41-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   -   EUCTR2013-002191-41-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002191-41-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Standard lymphodepletion regimen
   Arcellx, Inc.
      2025   Phase 1   NCT06626919   United States
   Kyverna Therapeutics
      2024   Phase 2   NCT06193889   Germany;United States
Steroid drug
   Peking Union Medical College Hospital
      2023   -   NCT06006832   China
Subcutaneous immunoglobulins
   St. Louis University
      2011   Phase 1   NCT01828294   United States
Sufentanil
   Shenzhen Guangming District People's Hospital
      2024   Phase 4   ChiCTR2400084414   China
Sugammadex
   Beijing Tongren Hospital
      2024   -   NCT06436768   China
   Beijing Tongren Hospital, Capital Medical University
      2022   -   ChiCTR2300073727   China
Sulfate
   Aarhus University Hospital
      2019   Phase 3   EUCTR2019-000895-40-DK   Denmark
Syngeneic bone marrow transplantation
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
SYS6020 injection
   CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
      2025   Phase 1   NCT06688435   China
T-peptide-CRM197 conjugate
   CuraVac Europe SA
      2017   Phase 2;Phase 3   EUCTR2017-000323-27-NL   Belgium;Netherlands
      2017   Phase 2;Phase 3   EUCTR2017-000323-27-BE   Belgium;Netherlands
Tacrolimus
   Astellas Pharma Inc
      2006   Phase 3   NCT00309101   Japan
      2006   Phase 3   NCT00309088   Japan
   Department of Neurology, Chiba University Graduate School of Medicine
      2012   -   JPRN-UMIN000007679   Japan
      2012   -   JPRN-UMIN000007671   Japan
   Kansai medical university
      2014   -   JPRN-UMIN000015019   Japan
   Peking University People's Hospital
      2024   Phase 2   ChiCTR2400084715   China
      2024   Phase 2   ChiCTR2400083801   China
   Shijiazhuang People's Hospital
      2022   Phase 4   ChiCTR2200057193   China
   The Third Affiliated Hospital of Sun Yat-sen University
      2022   Phase 4   ChiCTR2200061488   China
Tacrolimus capsule
   Astellas Pharma Inc
      2011   Phase 3   NCT01325571   China
TAK-079
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States
   Takeda
      2020   Phase 2   NCT04159805   Canada;Italy;Poland;Serbia;Spain;United States
Telitacicept
   First Affiliated Hospital of Wenzhou Medical University
      2024   Phase 4   NCT06723548   -
   Peking University People's Hospital
      2024   Phase 2   ChiCTR2400084781   China
      2024   Phase 2   ChiCTR2400084715   China
   RemeGen Co., Ltd.
      2024   Phase 3   NCT06456580   Poland;United States
      2023   Phase 3   NCT05737160   China
   Xiangya Hospital of Central South University
      2023   Phase 0   ChiCTR2300075401   china
Telitacicept-only group
   First Affiliated Hospital of Wenzhou Medical University
      2025   -   NCT06827587   -
Tetanus vaccin
   Leiden University Medical Center
      2015   Phase 4   EUCTR2014-004344-35-NL   Netherlands
Thymectomy plus prednisone
   University of Alabama at Birmingham
      2006   Phase 3   NCT00294658   Argentina;Australia;Brazil;Canada;Chile;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States
Tocilizumab
   Department of Neurology, The Second Affiliated Hospital of Air Force Medical University
      2021   -   ChiCTR2100043273   China
   Peking University People's Hospital
      2024   Phase 2   ChiCTR2400084715   China
Tocilizumab injectable product
   Tang-Du Hospital
      2022   Phase 2   NCT05067348   China
Tocilizumab injection
   Tang-Du Hospital
      2023   Phase 2/Phase 3   NCT05716035   China
Tofacitinib 5 MG
   Huashan Hospital
      2020   Early Phase 1   NCT04431895   China
Tolebrutinib
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 3   EUCTR2021-003898-59-IT   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
   Sanofi-Aventis Recherche & Développement
      2022   Phase 3   EUCTR2021-003898-59-PL   Argentina;Brazil;Canada;China;Czechia;Germany;Hungary;Italy;Japan;Mexico;Poland;Russian Federation;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003898-59-ES   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2021-003898-59-HU   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
   Tanaka Tomoyuki
      2022   Phase 3   JPRN-jRCT2031220158   Canada;China;Hungary;Italy;Japan;Poland;Spainm;United Kingdo;United States
Tolebrutininb
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 3   EUCTR2021-003898-59-IT   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
   Sanofi
      2021   Phase 3   NCT05132569   Canada;China;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
   Sanofi-Aventis Recherche & Développement
      2022   Phase 3   EUCTR2021-003898-59-ES   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2021-003898-59-HU   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
Ucar T-cell
   Tianjin Huanhu Hospital
      2025   Early Phase 1   NCT06939166   China
Ucar T-cell group
   Zhejiang University
      2025   Early Phase 1   NCT06933563   China
UCB7665
   UCB Biopharma S.P.R.L.
      2017   Phase 2   NCT03052751   Belgium;Canada;Czechia;Denmark;Germany;Spain;United States
   UCB Biopharma SPRL
      2020   Phase 3   EUCTR2019-000969-21-ES   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000969-21-HU   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-HU   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-GB   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-ES   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002698-36-ES   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States
      2017   Phase 2   EUCTR2016-002698-36-DK   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States
      2017   Phase 2   EUCTR2016-002698-36-DE   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States
      2017   Phase 2   EUCTR2016-002698-36-CZ   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States
      2017   Phase 2   EUCTR2016-002698-36-BE   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States
   UCB Biopharma SRL
      2023   Phase 3   EUCTR2022-003870-21-IT   Canada;Georgia;Germany;Italy;Japan;Poland;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003230-20-FR   Belgium;Canada;China;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003230-20-BE   Belgium;Canada;China;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-PL   Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-IT   Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-HU   Belgium;Canada;China;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-GB   Belgium;Canada;China;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-DK   Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-DE   Belgium;Canada;China;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003230-20-CZ   Belgium;Canada;China;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-000969-21-PL   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-000969-21-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-000969-21-GB   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-000969-21-DE   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-000969-21-CZ   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000969-21-DK   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-PL   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-DK   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-DE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-CZ   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000968-18-BE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States
Ultomiris
   ALEXION PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2018-003243-39-IT   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States
   Alexion Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2018-003243-39-PT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003243-39-GB   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003243-39-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-NL   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003243-39-DK   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2024   -   NCT06312644   United States
Ultomiris 1,100 MG/11 ML
   Alexion Pharmaceuticals Incorporated
      2019   Phase 3   EUCTR2018-003243-39-DE   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
Universal bcma CAR-T
   Xuanwu Hospital, Beijing
      2025   Early Phase 1   NCT06485232   China
Universal CD19 CAR-T
   Xuanwu Hospital, Beijing
      2025   Early Phase 1   NCT06485232   China
Uplizna
   Viela Bio, Inc. /Horizon Therapeutics Ireland DAC
      2021   Phase 3   EUCTR2020-000949-14-DE   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Türkiye;Ukraine;United Kingdom;United States
   Viela Bio, Inc./Horizon Therapeutics Ireland DAC
      2021   Phase 3   EUCTR2020-000949-14-DK   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Velamox
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States
Withdraw ALL immunosuppresants
   Peking Union Medical College Hospital
      2023   -   NCT06006832   China
YTB323
   Novartis Pharmaceuticals
      2025   Phase 1/Phase 2   NCT06704269   France;Japan;United States
Zilbrysq
   Centre Hospitalier Universitaire de Nice
      2025   -   NCT06815133   France
Zilucoplan
   Ra Pharmaceuticals, Inc.
      2021   Phase 3   EUCTR2019-001565-33-PL   Canada;France;Germany;Italy;Japan;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001565-33-NO   Canada;France;Germany;Italy;Japan;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001565-33-IT   Canada;France;Germany;Italy;Japan;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001565-33-ES   Canada;France;Germany;Italy;Japan;Norway;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001564-30-NO   Canada;France;Germany;Italy;Japan;Korea, Republic of;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001564-30-IT   Canada;France;Germany;Italy;Japan;Norway;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001564-30-ES   Canada;France;Germany;Italy;Japan;Norway;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001564-30-DE   Canada;France;Germany;Italy;Japan;Korea, Republic of;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 3   NCT04115293   Canada;France;Germany;Italy;Japan;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001565-33-GB   Canada;France;Germany;Italy;Japan;Norway;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001564-30-GB   Canada;France;Germany;Italy;Japan;Norway;Spain;United Kingdom;United States
   UCB Biopharma SRL
      2024   Phase 3   NCT06471361   Poland;United Kingdom;United States
      2024   Phase 3   NCT06435312   Italy;Korea, Republic of;Poland;United Kingdom;United States
      2024   Phase 2/Phase 3   NCT06055959   Italy;Korea, Republic of;Poland;United Kingdom;United States
      2022   Phase 3   NCT05514873   United States
      2019   Phase 3   NCT04225871   Canada;France;Germany;Italy;Japan;Norway;Poland;Spain;United Kingdom;United States